Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783010 | 0.87 | MEN1 (0.40) | MEN1KMT2ASLC6A5HRH2HRH1 | |
| SCHEMBL6784068 | 0.79 | PTGES (0.38) | MEN1KMT2ASLC6A5HRH2HRH1 | |
| SCHEMBL6905985 | 0.77 | MMP9 (0.43) | HRH2HRH1 | |
| SCHEMBL6897762 | 0.77 | HRH2 (0.42) | MEN1KMT2ASLC6A5HRH2HRH1 | |
| SCHEMBL6783199 | 0.76 | MEN1 (0.41) | MEN1KMT2ASLC6A5HRH2HRH1 | |
| SCHEMBL6784626 | 0.72 | PTGES (0.40) | MEN1KMT2ASLC6A5HRH2HRH1 | |
| SCHEMBL6895994 | 0.71 | MMP1 (0.49) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6897768 | 0.70 | S1PR1 (0.48) | TSHR | |
| SCHEMBL6783763 | 0.69 | SPHK1 (0.42) | MEN1KMT2A | |
| SCHEMBL5222706 | 0.68 | TP53 (0.54) | TSHRPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710060-B2 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| EP-1182192-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | SCN5A, RYR2, SCN1B | MEN1 4123/4885KMT2A 2156/4885SLC6A5 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.